Boyu Qin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Boyu Qin

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Frontiers in Immunology|April 29, 2021

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With ChemotherapyLiangliang Wu, Shengzhi Xie, Lingxiong Wang, et al.

Cancer Innovation|December 13, 2023

A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancerZheng Zhang, Yadi Zhang, Chuanling Liu, et al.

Immunotherapy|March 24, 2022

Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumorsQi Song, Bo Yang, Wei Sheng, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Frontiers in Immunology|April 29, 2021

Cancer Innovation|December 13, 2023

A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancerZheng Zhang, Yadi Zhang, Chuanling Liu, et al.

Immunotherapy|March 24, 2022

Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumorsQi Song, Bo Yang, Wei Sheng, et al.

Pageof 4